Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a
limited understanding of its clinical pathogenic spectrum of infection and disease …

Background Since the publication of the British Thoracic Society (BTS) Guideline on the
'Management of opportunistic mycobacterial infections' in 2000, our understanding of the …

Abstract Background. Individuals infected with Mycobacterium tuberculosis (Mtb) may
develop symptoms and signs of disease (tuberculosis disease) or may have no clinical …

Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …

Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the
newest version, are the only World Health Organization (WHO)‐recommended rapid tests …

The rapid diagnosis of pathogens is crucial in the early stages of treatment of diseases
where the choice of the correct drug can be critical. Although conventional cell culture-based …

Tuberculosis is a public health problem worldwide, including in the United States—
particularly among immunocompromised patients and other high-risk groups. Tuberculosis …

Background Accurate, rapid detection of tuberculosis (TB) and TB drug resistance is critical
for improving patient care and decreasing TB transmission. Xpert® MTB/RIF assay is an …

There are 9 million cases of active tuberculosis reported annually; however, an estimated
one-third of the world's population is infected with Mycobacterium tuberculosis and remains …

Background While tuberculosis incidence and mortality are declining in South Africa,
meeting the goals of the End TB Strategy requires an invigorated programmatic response …